ANORO ELLIPTA

Umeclidinium/Vilanterol

ANORO ELLIPTA

LAMALABA DPI

Umeclidinium / Vilanterol · GlaxoSmithKline

Clinical Reference

Active Medication & Mechanism

Umeclidinium bromide LAMA
62.5 mcg per blister

Long-acting muscarinic antagonist (anticholinergic). Blocks M3 muscarinic receptors on airway smooth muscle, inhibiting acetylcholine-mediated bronchoconstriction.
Vilanterol trifenatate LABA
25 mcg per blister

Long-acting beta2-adrenergic agonist. Stimulates beta2-receptors producing sustained bronchodilation (≥24 hours at once-daily dosing).

FDA-Approved Dosing by Indication

// approval varies by strength + age

COPD

1/1 approved regimens

Strength	Population	Dose & Frequency	Total Daily	Status
62.5/25 mcg	Adults (≥18 years)	1 inhalation once daily Long-term, once-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema.	62.5/25 mcg	FDA Approved

62.5/25 mcg FDA Approved

Pop · Adults (≥18 years)

1 inhalation once daily

Long-term, once-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema.

Total · 62.5/25 mcg

Asthma

0/1 approved regimens

Strength	Population	Dose & Frequency	Total Daily	Status
Any strength	All patients	—	—	Not Approved Anoro Ellipta is NOT indicated for asthma. LABA without ICS in asthma increases risk of serious asthma-related events.

Any strength Not Approved

Pop · All patients

—

Total · — Anoro Ellipta is NOT indicated for asthma. LABA without ICS in asthma increases risk of serious asthma-related events.

Acute Use

0/1 approved regimens

Strength	Population	Dose & Frequency	Total Daily	Status
Any strength	Acute bronchospasm / rescue	—	—	Not Approved Not indicated for relief of acute bronchospasm. Use a SABA.

Any strength Not Approved

Pop · Acute bronchospasm / rescue

—

Total · — Not indicated for relief of acute bronchospasm. Use a SABA.